Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. (Q52895479)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 December 2015

Language	Label	Description	Also known as
English	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.	scientific article published on 15 December 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Annalisa Chiappella

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Roberto Marasca

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pellegrino Musto

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M Christina Cox

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

7

object named as

Monica Tani

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Renato Zambello

10

object named as

Renato Zambello

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Maria Giuseppina Cabras

9

object named as

Maria Giuseppina Cabras

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Annalisa Arcari

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Luca Zanlari

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Patrizia Bernuzzi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Vanessa Valenti

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alberto Santagostino

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Fiorella Ilariucci

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giuseppe Carli

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Paolo Savini

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Dario Marino

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Francesco Ghio

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Massimo Gentile

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Daniele Vallisa

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

15 December 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1823-1830

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

The epidemiology of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine: rebirth of an old drug

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1106536

21 January 2018

Identifiers

10.3109/10428194.2015.1106536

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26666433%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52895479&oldid=1858457880"